UBS Group’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-12,100
| Closed | -$289K | – | 10374 |
|
|
2021
Q1 | $289K | Sell |
12,100
-29,609
| -71% | -$550K | ﹤0.01% | 5230 |
|
|
2020
Q4 | $609K | Buy |
41,709
+10,902
| +35% | +$144K | ﹤0.01% | 4446 |
|
|
2020
Q3 | $437K | Sell |
30,807
-15,236
| -33% | -$233K | ﹤0.01% | 4300 |
|
|
2020
Q2 | $677K | Sell |
46,043
-19,042
| -29% | -$193K | ﹤0.01% | 3881 |
|
|
2020
Q1 | $268K | Sell |
65,085
-26,592
| -29% | -$125K | ﹤0.01% | 4491 |
|
|
2019
Q4 | $441K | Buy |
91,677
+31,044
| +51% | +$171K | ﹤0.01% | 4949 |
|
|
2019
Q3 | $367K | Buy |
60,633
+44,902
| +285% | +$280K | ﹤0.01% | 4798 |
|
|
2019
Q2 | $102K | Buy |
15,731
+8,621
| +121% | +$60.7K | ﹤0.01% | 5365 |
|
|
2019
Q1 | $50K | Sell |
7,110
-16,894
| -70% | -$111K | ﹤0.01% | 5558 |
|
|
2018
Q4 | $116K | Buy |
24,004
+6,636
| +38% | +$34.6K | ﹤0.01% | 5418 |
|
|
2018
Q3 | $128K | Buy |
17,368
+5,773
| +50% | +$42.4K | ﹤0.01% | 5370 |
|
|
2018
Q2 | $74K | Buy |
11,595
+10,768
| +1,302% | +$71.2K | ﹤0.01% | 5674 |
|
|
2018
Q1 | $5K | Sell |
827
-4,029
| -83% | -$20K | ﹤0.01% | 7268 |
|
|
2017
Q4 | $20K | Buy |
4,856
+2,208
| +83% | +$13.3K | ﹤0.01% | 6572 |
|
|
2017
Q3 | $25K | Buy |
2,648
+348
| +15% | +$3.62K | ﹤0.01% | 6303 |
|
|
2017
Q2 | $27K | Sell |
2,300
-1,080
| -32% | -$13.8K | ﹤0.01% | 6088 |
|
|
2017
Q1 | $43K | Sell |
3,380
-5,327
| -61% | -$64.1K | ﹤0.01% | 5633 |
|
|
2016
Q4 | $106K | Buy |
8,707
+3,876
| +80% | +$46K | ﹤0.01% | 5251 |
|
|
2016
Q3 | $57K | Sell |
4,831
-2,114
| -30% | -$20.4K | ﹤0.01% | 5412 |
|
|
2016
Q2 | $60K | Buy |
6,945
+6,245
| +892% | +$42.8K | ﹤0.01% | 5384 |
|
|
2016
Q1 | $4K | Sell |
700
-385
| -35% | -$2.14K | ﹤0.01% | 7125 |
|
|
2015
Q4 | $8K | Sell |
1,085
-11,615
| -91% | -$89.2K | ﹤0.01% | 7456 |
|
|
2015
Q3 | $100K | Sell |
12,700
-9,500
| -43% | -$87.9K | ﹤0.01% | 5239 |
|
|
2015
Q2 | $201K | Buy |
22,200
+1,000
| +5% | +$10.1K | ﹤0.01% | 4866 |
|
|
2015
Q1 | $275K | Sell |
21,200
-2,841
| -12% | -$37.1K | ﹤0.01% | 4629 |
|
|
2014
Q4 | $327K | Buy |
+24,041
| New | +$269K | ﹤0.01% | 4582 |
|
UBS Group's GNMK Position: Q2 2021 in Review
UBS Group sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 12,100 shares — an estimated $289K sold.
UBS Group first reported a position in GNMK in Q4 2014 and held it in 26 quarters. The position peaked at $677K in Q2 2020. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- UBS Group reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- UBS Group sold 12,100 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $289K.
- UBS Group first reported a position in GenMark Diagnostics, Inc in Q4 2014 and held it in 26 quarters.
- UBS Group's GenMark Diagnostics, Inc position peaked at $677K in Q2 2020.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.